Skip to main content
Search
Main content
Sci Adv
Published

In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease.

Authors

Georg Meisl, Eric Hidari, Kieren Allinson, Timothy Rittman, Sarah L DeVos, Justin S Sanchez, Catherine K Xu, Karen E Duff, Keith A Johnson, James B Rowe, Bradley T Hyman, Tuomas P J Knowles, David Klenerman

Abstract

Both the replication of protein aggregates and their spreading throughout the brain are implicated in the progression of Alzheimer’s disease (AD). However, the rates of these processes are unknown and the identity of the rate-determining process in humans has therefore remained elusive. By bringing together chemical kinetics with measurements of tau seeds and aggregates across brain regions, we can quantify their replication rate in human brains. Notably, we obtain comparable rates in several different datasets, with five different methods of tau quantification, from postmortem seed amplification assays to tau PET studies in living individuals. Our results suggest that from Braak stage III onward, local replication, rather than spreading between brain regions, is the main process controlling the overall rate of accumulation of tau in neocortical regions. The number of seeds doubles only every ∼5 years. Thus, limiting local replication likely constitutes the most promising strategy to control tau accumulation during AD.

PMID:34714685 | DOI:10.1126/sciadv.abh1448

UK DRI Authors

David Klenerman

Prof Sir David Klenerman

Group Leader

Determining how protein clumps form, damage the brain and change as the different neurodegenerative diseases develop to know which ones to target for therapies

Prof Sir David Klenerman